APICES CRO

We are an European full services #CRO. We give added value to our #clinicalresearch projects.
#clinialtrials #quality

[Tom Powles @tompowles1]

The FDA approves the signatera ctDNA assay for muscle invasive bladder cancer patients post surgery.

This is based on the results of Imvigor011 study (atezo vs placebo in ctDNA positives, surveillance for the ctDNA negatives).

It opens a new chapter for personalised therapy in urothelial cancer. Focusing on early treatment for those patients that need it and sparing those at lower risk potentially harmful treatment makes sense.

‘It is the first companion diagnostic approval in the field of blood-based MRD.’

https://t.co/dGAIblVrzc

[Daniel Castellano @cdanicas]

❤️ Carrera contra el Cáncer 2026!! 🏃‍♂️🏃‍♀️🏃‍♂️🏆🏆🙌🙌
🎯@GuardConsortium presente en la lucha contra el cáncer de vejiga!!🩸@ContraCancerEs @GuardConsortium @CANVES_ES @danaeurogenomics @myESMO @ASCO @ASCOPres @tompowles1 @drenriquegrande @aaoncoclinica

[Tom Powles @tompowles1]

The positive CREST study (BCG + Sasanlimab) in NMIBC was published today (Neal Shore et al). #ASCO25

[Daniel Castellano @cdanicas]

🎯 #ASCO2025 Ev-302 update data in regards of ORR. @shilpaonc >> OS for responders pts ( more in CR pts-not reached) Ev-Pembro continue showing the efficacy in 1L mUC!
@OncoAlert @tompowles1 @DrYukselUrun @GuardConsortium @ASCO @PGrivasMDPhD

[Enrique Grande @drenriquegrande]

#ASCO25 abstracts titlkes are out!!!!!
https://t.co/ybAeFhH4He
Much Looking forward to seeing the exciting new data in GU tumors!!!!
See you all in Chicago!!!! @ASCO @ASCOPost @DrChoueiri @tompowles1 @shilpaonc @Heijden @motzermd @GuardConsortium

[Daniel Castellano @cdanicas]

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer | Pfizer First phase III study with ICI’s in NMIBC!!👏👏👏 https://t.co/GMKuCSbtom

[Erman Akkus @Erman_Akkus]

📖🇩🇪German guideline for esophageal SCC and adenoca
@myESMO

✅Excellent guideline from diagnosis, imaging to nutrition, palliative care

👉https://t.co/jjHhO4xIMZ

PS: I think there is a typing error in the algorithm of SCC. It should be "preoperative CRT" instead of "preoperative chemotherapy"

@OncoAlert @DenizCanGuven1 #cancer #oncology #MedX

[APICES CRO @ApicesSpain]

🌟 ESCC Innovation 🌟

The Phase III RATIONALE 302 trial is exploring tislelizumab (PD-1 inhibitor) for esophageal squamous cell carcinoma (ESCC), showing promising results in survival and quality of life.

At @ApicesSpain we’re committed to advancing #oncology research. #CRO

[APICES CRO @ApicesSpain]

New hope for #MultipleMyeloma! #Clinicaltrials are achieving promising results for patients. Phase III TILVANCE-30 trial, Phase II IOV-COM-202 trial for metastatic #melanoma and a Phase I trial studying the combination of Fianlimab and Cemiplimab for advanced melanoma stand out.

[APICES CRO @ApicesSpain]

🌍The @WHO recommends the R21/Matrix-M vaccine for malaria prevention in children. With high efficacy, it’s a major step forward in the fight against malaria, particularly in Africa.

#Malaria #Vaccines #CRO #ClinicalResearch

https://t.co/XMseSCTKXr

[APICES CRO @ApicesSpain]

🔬 Promising results 𝗳𝗿𝗼𝗺 𝗮 𝗣𝗵𝗮𝘀𝗲 𝗜𝗜𝗜 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹, the @EMA_News has approved 𝗹𝗲𝗰𝗮𝗻𝗲𝗺𝗮𝗯 to slow the progression of symptoms associated with #𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗱𝗶𝘀𝗲𝗮��𝗲.
https://t.co/lhq8iXSrbA

#CRO #ClinicalResearch #ClinicalTrials

[APICES CRO @ApicesSpain]

In the fight against #HIV, the most recent advances in #clinicaltrials offer new hope for a future without this disease. The VIR-1388 trial, currently in phase I, aims to generate a strong and lasting immune response, which could transform HIV prevention.
#CRO #ClinicalResearch

[APICES CRO @ApicesSpain]

The STEM-PD #clinicaltrial is investigating the transplantation of dopamine-producing neurons derived from embryonic stem cells in patients with moderate #Parkinsons disease, aiming to replace the damaged cells and pave the way for regenerative therapies. 
https://t.co/oha8F5aJUK

[APICES CRO @ApicesSpain]

A patient achieved complete remission of a previously incurable #braintumor in a Phase I clinical trial through #CARTcell therapy. This breakthrough offers hope for pathologies once considered untreatable, and underscores the importance of #clinicaltrials. https://t.co/EFJRxZsZ8T

[APICES CRO @ApicesSpain]

At #ESMO2024, key advancements were presented in #clinicaltrials that are revolutionizing #lungcancer treatment. 
At @ApicesSpain, we are committed to the development of innovative treatments in #oncology, transforming cancer therapies and offering new hope to patients.
#CRO

[APICES CRO @ApicesSpain]

At @ApicesSpain we believe #patients should be at the heart of #clinicaltrials.

Through proactive engagement we ensure that studies are designed with their needs, concerns and hopes as a priority.

https://t.co/JeqSFuRPXt 

#CRO

[APICES CRO @ApicesSpain]

#Breastcancer is a major health challenge globally, with high morbidity and mortality. At the recent #ESMO24 congress, several promising new treatments were presented that could significantly improve outcomes for patients:
🎗️DESTINY-Breast06 trial
🎗️ ABIGAIL trial
#CRO #Oncology

[APICES CRO @ApicesSpain]

Promising #clinicaltrials show advances in bispecific antibodies and CAR-T therapies for #multiplemyeloma, offering hope for better outcomes and quality of life. #clinicalresearch

https://t.co/z9aOxcf46J

[APICES CRO @ApicesSpain]

Spain is the European country with the highest number of #CTIS authorized #clinicaltrials! This highlights the excellence of our healthcare system and investigators. #clinicalresearch

https://t.co/ZB4PeGf2J6

[APICES CRO @ApicesSpain]

🌟 Exciting news! A #clinicaltrial is testing a vaccine that could revolutionize #lungcancer treatment by activating the immune system. #CRO #Clinicalresearch

https://t.co/m59nXQPGXp